IGF1R and cancer: This study suggests that strategies to imbalance β-arrestin isoform expression toward β-arre2 downstream of the IGF-1R limit MAPK activation while reactivating a tumor suppressor, a strong double-hit system for therapeutic targeting in cancer cells.